• FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

  • 2024/06/21
  • 再生時間： 57 分
  • ポッドキャスト

FDA advisors say no to MDMA. What’s the impact? With Josh Hardman

無料で聴く

ポッドキャストの詳細を見る

  • サマリー

  • Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

    Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

    In this episode, we discuss:

    • The FDA advisory committee process and its implications for drug approvals
    • Functional unblinding and expectancy effects in psychedelic clinical trials
    • Potential impacts on the broader psychedelic medicine industry
    • The future of psychedelic-assisted psychotherapy protocols
    • Neuroplastogen development and non-hallucinogenic approaches
    • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

    Credits:

    Created by Greg Kubin and Matias Serebrinsky
    Host: Matias Serebrinsky & Greg Kubin
    Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

    Find us at businesstrip.fm and psymed.ventures
    Follow us on Instagram and Twitter!
    Theme music by Dorian Love
    Additional Music: Distant Daze by Zack Frank
    続きを読む 一部表示

あらすじ・解説

Greg and Matias interview Josh Hardman, founder and editor of Psychedelic Alpha, to discuss the recent FDA advisory committee meeting on Lykos Therapeutics’ MDMA-assisted therapy for PTSD.

Josh is a leading writer covering the intersection of psychedelics and business. He provided live reporting and analysis of the AdComm meeting.

In this episode, we discuss:

  • The FDA advisory committee process and its implications for drug approvals
  • Functional unblinding and expectancy effects in psychedelic clinical trials
  • Potential impacts on the broader psychedelic medicine industry
  • The future of psychedelic-assisted psychotherapy protocols
  • Neuroplastogen development and non-hallucinogenic approaches
  • Challenges around therapy, safety, and regulatory pathways for psychedelic medicines

Credits:

Created by Greg Kubin and Matias Serebrinsky
Host: Matias Serebrinsky & Greg Kubin
Produced by Jonathan A. Davis, Nico V. Rey & Caitlin Ner

Find us at businesstrip.fm and psymed.ventures
Follow us on Instagram and Twitter!
Theme music by Dorian Love
Additional Music: Distant Daze by Zack Frank
続きを読む 一部表示

FDA advisors say no to MDMA. What’s the impact? With Josh Hardmanに寄せられたリスナーの声

カスタマーレビュー：以下のタブを選択することで、他のサイトのレビューをご覧になれます。

Audible.co.jp

Amazon.co.jp
レビューはまだありません。